-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Initiates Coverage On Krystal Biotech with Outperform Rating, Announces Price Target of $400

Benzinga·08/14/2026 14:15:36
Listen to the news
RBC Capital analyst Lisa Walter initiates coverage on Krystal Biotech (NASDAQ:KRYS) with a Outperform rating and announces Price Target of $400.